FactSet (FDS) Announces Senior Notes Offering

FactSet Research Systems Inc. (NYSE: FDS) (NASDAQ: FDS), a global provider of integrated financial information, analytical applications, and industry-leading services, announced today the commencement of an offering of a series of five-year senior notes and a series of ten-year senior notes (collectively, the “Notes”) pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (the “SEC”). The Notes will be senior unsecured obligations of FactSet Research Systems Inc.

FactSet intends to use the net proceeds of the offering, together with borrowings under its proposed new senior unsecured credit facilities and cash on hand, to (a) finance the consideration for the proposed acquisition of CUSIP Global Services from S&P Global Inc. (the “CGS Transaction”), (b) refinance FactSet’s existing credit facilities and (c) pay transaction fees related to the proposed CGS Transaction.

BofA Securities, Inc. and PNC Capital Markets LLC are acting as joint book-running managers for the offering. The offering is being made only by means of a prospectus supplement and the accompanying base prospectus, which is filed as part of FactSet’s effective shelf registration statement on Form S-3, copies of which may be obtained by calling BofA Securities at 1-800-294-1322 or by email at [email protected] or PNC Capital Markets LLC at 1-855-881-0697. You may also obtain these documents for free by visiting EDGAR on the website of the Securities and Exchange Commission at www.sec.gov.

This press release will not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the notes or the guarantees in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Marvell names Dan Durn as CFO effective June 15, 2026
• Enliven Therapeutics prices upsized public offering at $37.50 per share
• Ascendis reports 5-year TransCon PTH data in hypoparathyroidism patients